Ascendis Pharma A/S · ASND · Next earnings

Ascendis Pharma A/S reports Wednesday, Nov 11, 2026

ASND reports before market open with consensus EPS at $0.89 and revenue at $409.4M. Last quarter: Ascendis: Product Revenue More Than Doubled as YUVIWEL Launch Accelerated

Reports Before market open7 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $0.89 Calendar consensus
Consensus revenue $409.4M Calendar consensus
Report date Nov 11, 2026 Wednesday, date estimated
Session Before market open 7 days away

Where ASND left off: FY2026 Q2

Full report

Ascendis: Product Revenue More Than Doubled as YUVIWEL Launch Accelerated

EPS surprise +92.4% Reported $3.29 vs $1.71
Revenue surprise +2.8% Reported $387.5M vs $376.8M
Stock move -3.6% Event window
Subsequent drift +7.0% Up to 20 sessions

Maintained; management continues to target more than EUR 500 million of operating cash flow in 2026.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • YUVIWEL faces regulatory uncertainty and ongoing BioMarin patent litigation.
  • YORVIPATH patient dropout during titration could affect continued growth.
  • Commercial expansion and patient-support execution remain important as the company broadens geographically.

Questions analysts left open

  • How much YUVIWEL growth reflects market expansion versus switches.
  • Timing of IND submissions and pipeline milestones.
  • Ongoing BioMarin ITC litigation and the timing of regulatory decisions.

Ask FN2 about ASND next report

Transcript, numbers and history already loaded
What should I watch for in ASND's next earnings report?How did ASND guide last quarter, and is consensus above or below that?Give me the bull and bear case going into ASND earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the ASND recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent ASND quarters

All ASND earnings
-3.6%FY2026 Q2+4.3%FY2026 Q1+0.6%FY2025 Q2-1.7%FY2025 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q2

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.